Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:46am, Monday, 17'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
10:30am, Monday, 17'th Feb 2025
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
12:06pm, Thursday, 13'th Feb 2025
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
10:46am, Thursday, 13'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
08:30am, Tuesday, 04'th Feb 2025
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results
SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opi
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:40am, Friday, 31'st Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 28'th Jan 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
10:56am, Monday, 27'th Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
11:06am, Tuesday, 14'th Jan 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
01:45pm, Friday, 10'th Jan 2025
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
12:30pm, Thursday, 09'th Jan 2025
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
07:00am, Wednesday, 08'th Jan 2025
Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY G
These 4 Stocks Boast Impressive Interest Coverage Ratios
11:35am, Monday, 06'th Jan 2025
LDOS, AMZN, HALO & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
08:30am, Monday, 06'th Jan 2025
SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT
